At a glance
What is it—and why does it matter?
Analytical performance included a detection limit of 10 pg/mL for both urine and plasma, and linearity with R2 > 0.9995. The peptide’s cyclic structure and high molecular weight are stated to hinder reliable analytical detection.
Sources for this introduction: [1] [2]
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
What is it?
A molecule, not a product name.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
How does it work?
Target, response, and disposition.
Mechanism
Analytical performance included a detection limit of 10 pg/mL for both urine and plasma, and linearity with R2 > 0.9995.
- Reported result
- Detection limit: 10 pg/mL; R2> 0.9995.
- Source records
- 1
- Independent studies
- 1
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The method achieved a detection limit of 10 pg/mL for urine and plasma (R2> 0.9995 in both cases), meeting the validation criteria for quantitative analysis.”
Sensitive and selective quantification of elcatonin in equine plasma and urine using LC-FAIMS-MS/MS. · Abstract
pubmed:42127554:40a72740265e:40a72740265e
What has been studied?
What the evidence says.
Study findings
The peptide’s cyclic structure and high molecular weight are stated to hinder reliable analytical detection.
- Source records
- 1
- Independent studies
- 1
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“However, its cyclic structure and high molecular weight hinder reliable detection.”
Sensitive and selective quantification of elcatonin in equine plasma and urine using LC-FAIMS-MS/MS. · Abstract
pubmed:42127554:40a72740265e:40a72740265e
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Research status + gaps
What still needs better answers?
- No publishable claim yet for: administration, contraindication, identity, interaction, regulatory, safety
- 10 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (2), assurance_score_below_0.72 (4), current_regulatory_source_required (4), extraction_ambiguity (10), high_risk_requires_regulatory_or_two_independent_sources (5), no_direct_support (5)
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- Sensitive and selective quantification of elcatonin in equine plasma and urine using LC-FAIMS-MS/MS. ↗
pubmed · published 2026-10-15 · retrieved 2026-08-26T08:42:26Z
Publication history and provenance
Version 3 · Automated assessment · 2026-08-26T20:21:51Z
f7682ffc4af70ed368df93b5976cf0c28e7bd688d416ff3d82a6c0b59d942cab